We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics reports Q3 EPS of 35 cents and revenues of $259.9 million, beating estimates.
Briumvi U.S. sales jump 52% to $232.6 million, fueled by physician adoption and patient growth.
TGTX raises 2026 global revenue view to $1 billion and expects Q4 U.S. Briumvi sales above $260 million.
TG Therapeutics (TGTX - Free Report) reported earnings of 35 cents per share for the third quarter of 2026, beating the Zacks Consensus Estimate of 28 cents. The company had reported earnings of $2.43 per share in the year-ago quarter.
Total revenues were $259.9 million, up 60.7% year over year, driven by strong demand for the company's sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $247 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia, Switzerland and certain other countries.
Shares of TG Therapeutics were up 5.9% on Nov. 9 following the better-than-expected earnings results as well as raised 2026 guidance.
The stock has surged 112.6% in the year-to-date period compared with the industry’s increase of 9.9%.
Image Source: Zacks Investment Research
TGTX's Q3 Earnings in Detail
The top line comprised product revenues from Briumvi and license, milestone, royalty and other revenues.
Total product revenues were $240 million in the reported quarter, reflecting a 50.7% year-over-year increase. These included $7.4 million in Briumvi sales to TGTX's ex-U.S. licensing partner, Neuraxpharm.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Briumvi's net product sales in the United States were $232.6 million in the third quarter, up approximately 52% year over year, supported by increasing physician adoption and a growing patient base.
License, milestone, royalty and other revenues totaled $19.9 million, compared with $2.4 million reported in the year-ago quarter.
Research and development (R&D) expenses increased 25.5% year over year to $51.3 million, primarily due to subcutaneous Briumvi manufacturing activities, secondary manufacturing expenses and ongoing clinical studies.
Selling, general and administrative (SG&A) expenses increased 27.3% year over year to $80.7 million, reflecting higher marketing expenditures and personnel costs associated with Briumvi commercialization.
As of Sept. 30, 2026, TG Therapeutics had cash, cash equivalents and investment securities worth $556.7 million, compared with $612.3 million as of June 30, 2026.
TGTX Raises 2026 Revenue Guidance
TG Therapeutics raised its full-year 2026 global revenue guidance to approximately $1 billion from the previous expectation of around $950 million, reflecting continued commercial momentum.
The company now expects U.S. Briumvi net product revenues between $915 million and $920 million, up from its previous guidance of $890 million to $905 million.
Management anticipates U.S. Briumvi sales exceeding $260 million in the fourth quarter, driven by accelerating new patient demand and broader physician adoption.
TGTX maintained its 2026 R&D and SG&A expense guidance, excluding stock-based compensation, at $450 million to $500 million.
TGTX's Recent Pipeline Updates
TG Therapeutics recently reported positive phase III ENHANCE study results, supporting a simplified single-infusion initiation regimen for Briumvi. Subject to regulatory approval, the company targets a potential launch around mid-2027.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for treating RMS in a pivotal phase III study. The company expects to announce top-line data from this study by the end of 2026 or in the first quarter of 2027, with a potential commercial launch targeted for 2028.
If successfully developed, the Briumvi SC formulation may eventually be available as a quick injection rather than a lengthy IV infusion, which could make treatment more convenient for patients.
Additionally, separate phase II studies are currently underway evaluating Briumvi in patients with myasthenia gravis (MG) who initially respond to treatment with the FcRn inhibitor efgartigimod as well as for treatment-resistant schizophrenia. Successfully developing Briumvi for additional indications will help TG Therapeutics reach a broader patient population and drive revenue growth.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
Over the past 30 days, estimates for Halozyme’s 2026 earnings per share have risen from $8.73 to $8.81, while estimates for 2027 have increased from $9.80 to $10.31 during the same time. HALO shares have surged 53% year to date.
Halozyme’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average negative surprise being 19.41%.
Over the past 30 days, estimates for Amneal’s 2026 earnings per share have risen from $1.03 to $1.04, while estimates for 2027 have increased from $1.16 to $1.19 during the same time. AMRX shares have rallied 68.9% year to date.
Amneal’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.21%.
Over the past 30 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.18 to $7.39, while estimates for 2027 have increased from $5.78 to $6.84 during the same time. COLL shares have plunged 46.6% year to date.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 10.53%.
View the Zacks #1 Rank List
Image: Bigstock
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
Key Takeaways
TG Therapeutics (TGTX - Free Report) reported earnings of 35 cents per share for the third quarter of 2026, beating the Zacks Consensus Estimate of 28 cents. The company had reported earnings of $2.43 per share in the year-ago quarter.
Total revenues were $259.9 million, up 60.7% year over year, driven by strong demand for the company's sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $247 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia, Switzerland and certain other countries.
Shares of TG Therapeutics were up 5.9% on Nov. 9 following the better-than-expected earnings results as well as raised 2026 guidance.
The stock has surged 112.6% in the year-to-date period compared with the industry’s increase of 9.9%.
Image Source: Zacks Investment Research
TGTX's Q3 Earnings in Detail
The top line comprised product revenues from Briumvi and license, milestone, royalty and other revenues.
Total product revenues were $240 million in the reported quarter, reflecting a 50.7% year-over-year increase. These included $7.4 million in Briumvi sales to TGTX's ex-U.S. licensing partner, Neuraxpharm.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Briumvi's net product sales in the United States were $232.6 million in the third quarter, up approximately 52% year over year, supported by increasing physician adoption and a growing patient base.
License, milestone, royalty and other revenues totaled $19.9 million, compared with $2.4 million reported in the year-ago quarter.
Research and development (R&D) expenses increased 25.5% year over year to $51.3 million, primarily due to subcutaneous Briumvi manufacturing activities, secondary manufacturing expenses and ongoing clinical studies.
Selling, general and administrative (SG&A) expenses increased 27.3% year over year to $80.7 million, reflecting higher marketing expenditures and personnel costs associated with Briumvi commercialization.
As of Sept. 30, 2026, TG Therapeutics had cash, cash equivalents and investment securities worth $556.7 million, compared with $612.3 million as of June 30, 2026.
TGTX Raises 2026 Revenue Guidance
TG Therapeutics raised its full-year 2026 global revenue guidance to approximately $1 billion from the previous expectation of around $950 million, reflecting continued commercial momentum.
The company now expects U.S. Briumvi net product revenues between $915 million and $920 million, up from its previous guidance of $890 million to $905 million.
Management anticipates U.S. Briumvi sales exceeding $260 million in the fourth quarter, driven by accelerating new patient demand and broader physician adoption.
TGTX maintained its 2026 R&D and SG&A expense guidance, excluding stock-based compensation, at $450 million to $500 million.
TGTX's Recent Pipeline Updates
TG Therapeutics recently reported positive phase III ENHANCE study results, supporting a simplified single-infusion initiation regimen for Briumvi. Subject to regulatory approval, the company targets a potential launch around mid-2027.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for treating RMS in a pivotal phase III study. The company expects to announce top-line data from this study by the end of 2026 or in the first quarter of 2027, with a potential commercial launch targeted for 2028.
If successfully developed, the Briumvi SC formulation may eventually be available as a quick injection rather than a lengthy IV infusion, which could make treatment more convenient for patients.
Additionally, separate phase II studies are currently underway evaluating Briumvi in patients with myasthenia gravis (MG) who initially respond to treatment with the FcRn inhibitor efgartigimod as well as for treatment-resistant schizophrenia. Successfully developing Briumvi for additional indications will help TG Therapeutics reach a broader patient population and drive revenue growth.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
TG Therapeutics, Inc. price-consensus-eps-surprise-chart | TG Therapeutics, Inc. Quote
TGTX's Zacks Rank & Other Stocks to Consider
TG Therapeutics currently carries a Zacks Rank #1 (Strong Buy)
Some other top-ranked stocks in the drug/biotech sector are Halozyme Therapeutics (HALO - Free Report) , Amneal Pharmaceuticals (AMRX - Free Report) and Collegium Pharmaceutical (COLL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Halozyme’s 2026 earnings per share have risen from $8.73 to $8.81, while estimates for 2027 have increased from $9.80 to $10.31 during the same time. HALO shares have surged 53% year to date.
Halozyme’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average negative surprise being 19.41%.
Over the past 30 days, estimates for Amneal’s 2026 earnings per share have risen from $1.03 to $1.04, while estimates for 2027 have increased from $1.16 to $1.19 during the same time. AMRX shares have rallied 68.9% year to date.
Amneal’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.21%.
Over the past 30 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.18 to $7.39, while estimates for 2027 have increased from $5.78 to $6.84 during the same time. COLL shares have plunged 46.6% year to date.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 10.53%.